Survivin and mage-a9 dual-targeted immunotherapy
AssigneeImmunovaccine Technologies Inc.
InventorsValerie PICARD, Alain BERGERON, Yves FRADET, Stephan FISET, Yogesh BRAMHECHA, Lisa MACDONALD
Life of this patent
Estimating the term…
Abstract
The present application relates generally to methods for treating tumors, and in particular to methods for using peptides of both survivin and MAGE-A9 in dual-targeted immunotherapy that generates targeted T cell response against these two tumor antigens.
Claims109
A pharmaceutical composition for delivering at least two T cell activation therapeutics to a subject comprising:
- i) at least two T cell activation therapeutics;
- ii) one or more lipid-based structures;
- and iii) a carrier, wherein the at least two T cell activation therapeutics comprise at least one survivin antigen and at least one melanoma-associated antigen 9 (MAGE-A9) antigen.
A method of treating a tumor in a subject, said method comprising administering to the subject a composition for delivering at least two T cell activation therapeutics, the composition comprising:
- i) at least two T cell activation therapeutics;
- ii) one or more lipid-based structures;
- and iii) a carrier, wherein the at least two T cell activation therapeutics comprising at least one survivin antigen and at least one melanoma-associated antigen 9 (MAGE-A9) antigen.
Dependencies are inferred from the claim text.